Introduction
Omnicare, LLC and 109 affiliated debtors filed voluntary Chapter 11 petitions on September 22, 2025, in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division. The case has since moved well past the filing stage, with a sale order and a confirmed plan on the docket.
This guide covers the case number, financial ranges, litigation context, key parties, official resources, and how to follow future filings.
Freshness note: This summary reflects the docket as of October 20, 2026. Verify current motions, deadlines, claims instructions, and case status through the official court docket and Stretto's Omnicare case website before relying on any detail here.
Key Takeaways
- Lead case 25-80486 (SGJ) was filed September 22, 2025, in N.D. Texas, with 110 debtors at filing.
- The court approved a sale of substantially all assets to GenieRx on May 13, 2026, and confirmed the plan on September 18, 2026.
- A $110 million DIP facility funded operations during the case.
- Confirmation is not the same as sale closing or the plan's effective date.
What the Omnicare Chapter 11 Docket Shows
Docket snapshot
| Item | Detail |
|---|---|
| Lead debtor | Omnicare, LLC |
| Court | U.S. Bankruptcy Court, N.D. Texas, Dallas Division |
| Case number | 25-80486 (SGJ), jointly administered |
| Judge | Stacey G. C. Jernigan |
| Chapter | 11 |
| Filing date | September 22, 2025 |
| Debtors at filing | 110 |
One caution on the financial ranges. Compscript, LLC's petition (case 25-80516) reports consolidated assets of $100,000,001 to $500,000,000 and liabilities of $1,000,000,001 to $10,000,000,000. It also checks that funds will be available for unsecured creditors.
Treat these as consolidated estimates, not standalone Omnicare, LLC figures and not a guaranteed recovery. Confirm against the lead petition or schedules.
Official sources
- The N.D. Texas bankruptcy court website and case search, plus PACER
- Stretto's case site, with the debtor list, docket, claims page, petitions, and first-day pleadings
- OmnicareRestructuring.com, the company's case information site
Look at the whole debtor list
Omnicare is not a single legal entity. Stretto lists 110 debtors at filing, and Omnicare Resources, LLC's separate case was later dismissed by order dated April 14, 2026. Check each entity you care about against the petition and docket.
Ownership
CVS Health's September 22, 2025 SEC filing describes Omnicare, LLC as a wholly owned indirect subsidiary. That is equity ownership, which is different from creditor status. The filing does not establish each affiliate's immediate owner, so check the schedules for that.
What has changed
- Sept. 24, 2025: Interim DIP order entered
- Nov. 3, 2025: Final DIP order entered
- Dec. 3, 2025: Bar-date order entered
- May 13, 2026: Sale to GenieRx approved
- July 1, 2026: Compromise motion addressing the DOJ judgment and CVS estate claims
- Sept. 18, 2026: Second amended joint plan confirmed
Stretto's case page listed hearings for October 26, October 27, and December 3, 2026. Those are scheduled dates, not outcomes.
Why Omnicare Filed and What Chapter 11 Is Intended to Accomplish
The litigation
Keep three things separate: allegations, findings, and Omnicare's position.
- Allegations: In a December 2019 complaint, the United States alleged Omnicare and CVS caused prescriptions to be dispensed without valid prescriptions. These are pleading allegations.
- Findings: On April 29, 2025, DOJ announced a jury found Omnicare liable, with more than 3 million false claims and $135,592,814 in assessed damages. The August 18, 2025 judgment lists $948,778,444.10 against Omnicare.
- Omnicare's position: Its release called the case one of technical pharmacy-law violations based on practices the government knew about, and called the penalty extreme and, in its view, unconstitutional.
A 2026 compromise filing says Omnicare and CVS would dismiss their appeals with prejudice after the agreement takes effect. The proposed DOJ arrangement calls for at least $440 million in total payments: $130 million from CVS and at least $310 million from estate distributions.
Industry pressure
The Debtors' disclosure statement cites several operating pressures:
- Inflation and a tight labor market
- Medicare policy changes and declining reimbursement
- Medicare Advantage shifts and industry consolidation
- Reduced occupancy in long-term-care facilities
Chapter 11 in practice
According to U.S. Courts, Chapter 11 is a reorganization process in which the debtor generally stays in possession while operating. That buys time to obtain financing, preserve operations, sell assets, or negotiate a plan.
DIP financing
Omnicare announced a $110 million DIP facility subject to court approval. The final order was entered November 3, 2025, and the later disclosure statement identifies JMB Capital Partners Lending, LLC as lender.
Restructuring, sale, and plan
These are different events. A Section 363 asset sale is a court-authorized transaction. A plan confirmation is a separate order. Here, the court approved the sale on May 13 and confirmed the plan on September 18. Plan effectiveness depends on sale closing and other conditions.
Omnicare's Business, CVS Ownership, and Earlier Sale Strategy
Omnicare provides pharmacy and clinical-care services to long-term-care providers, including skilled-nursing and assisted-living settings.
CVS Pharmacy acquired Omnicare around August 18, 2015, according to the Debtors' disclosure statement. The bankruptcy covers the named debtor entities, not every CVS business.
In a May 31, 2023 Form 8-K, CVS said it determined during 2022 that long-term care was no longer a strategic asset and committed to a sale plan. That earlier sale plan is separate from the 2025 Chapter 11 process.
Ownership matters to docket readers because control shapes who negotiates, who funds, and who recovers. Watch these filings for ownership and control changes:
- Petition and schedules
- Financing documents
- Sale and plan materials
What the Case Means for Creditors, Employees, Vendors, and Customers
Prepetition versus postpetition
Prepetition claims arise from obligations before September 22, 2025. Postpetition obligations arise after that date.
Omnicare said it expected, subject to court approval, to continue employee wages and benefits and to pay vendors in full under normal terms for goods and services provided after filing. Those are stated intentions, not guarantees on disputed invoices.
Claims deadlines
The December 3, 2025 bar-date order set a general deadline of February 2, 2026 and a governmental deadline of March 23, 2026, both at 4:00 p.m. CT. Both deadlines have passed. Stretto's claims page has the forms and contact details.
Creditors and vendors should also review:
- Administrative expense treatment under 11 U.S.C. § 503, including § 503(b)(9) for qualifying goods delivered within 20 days before filing
- Setoff rights under § 553
- Reclamation under § 546(c), which carries strict written-demand deadlines
Customers
Omnicare said pharmacy and clinical services would continue without disruption. Customers should rely on direct company communications and court-approved developments for current information.
How to Monitor the Omnicare Bankruptcy Docket and What Happens Next
Monitoring checklist
- Petition and first-day motions
- DIP financing orders and cash-management materials
- Employee, benefits, and vendor-payment orders
- Schedules and statements
- Claims notices
- Hearing calendars
Typical milestones
First-day relief, financing approval, claims administration, a sale process, disclosure statement and plan filings, and confirmation. If a case changes direction, it can be converted or dismissed. Omnicare has passed most of these. Sale closing and plan effectiveness are the open items.
Reading docket entries
- Check who filed it.
- Identify the document type.
- Note the hearing date and objection deadline.
- Read the requested relief.
- Confirm whether an order has actually been entered. A motion is not an order.
Keep a timeline
Record each material filing, ruling, deadline, advisor appointment, financing development, sale milestone, and plan event. The August 10, 2026 disclosure statement projected 100% recovery for general unsecured claims, 46.2% for the DOJ claim, and 0% for CVS prepetition claims. Those are estimates, not distributions.
Research tools
BankruptcyData, a Massachusetts-based provider operating since 1986, offers court-document research, docket tracking, advisor and stakeholder data, and historical case outcomes for professionals following cases like this one. For authoritative filings and deadlines, use the court and Stretto.
Frequently Asked Questions
Is Omnicare being sold?
Yes. The court approved a sale of substantially all assets to GenieRx Holdings LLC on May 13, 2026. Closing was expected later in 2026; as of October 20, 2026, official closing confirmation was not readily available on the docket.
Why is CVS selling Omnicare?
CVS said in 2023 that long-term care was no longer a strategic asset. Omnicare's 2025 filing separately cited the New York litigation and industry financial pressures.
Who owns Omnicare pharmacy?
At filing, CVS Health described Omnicare, LLC as a wholly owned indirect subsidiary. Check the petition and schedules for each debtor's ownership.
What is going to happen to Omnicare?
The court confirmed the plan on September 18, 2026, and approved the GenieRx sale. Effectiveness depends on closing and other conditions, so watch the docket.
Is confirmation the same as sale closing?
No. Confirmation approves the plan. The plan takes effect only after conditions, including sale closing, are met.
